Jesus A. Ocana

Jesus A. Ocana

Auto-generated profile, based on publicly available information

Jesus A. Ocana

Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SSSarita Sehra
Sarita Sehra
ASAna P.M. Serezani
Ana P.M. Serezani
JOJesus A. Ocaña
Jesus A. Ocaña
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers
MKMark H. Kaplan
Mark H. Kaplan

30 April 2012 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
Ravi SahuRavi Sahu
Ravi Sahu
MTMatthew J. Turner
Matthew J. Turner
SDSonia DaSilva-Arnold
Sonia DaSilva-Arnold
BRBadri M. Rashid
Badri M. Rashid
JOJesus A. Ocana
Jesus A. Ocana
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers
Ubiquitous pro-oxidative stressor ultraviolet B radiation (UVB) to human or mouse skin generates platelet-activating factor (PAF) and novel oxidatively modified glycerophosphocholines (Ox-GPCs) with PAF-receptor (PAF-R) agonistic activity. These lipids mediate systemic immunosuppression in a process involving IL-10. The current studies sought to determine the functional significance of UVB-mediated systemic immunosuppression in an established model of murine melanoma. We show that UVB irradiation augments B16F10 tumor growth and is dependent on host, but not melanoma cell; PAF-R-expression as UVB or the PAF-R agonist, carbamoyl PAF (CPAF), both promote B16F10 tumor growth in wild-type (WT) mice, independent of whether B16F10 cells express PAF-Rs, but do not augment tumor growth in Pafr −/− mice. UVB-mediated augmentation of experimental murine tumor growth was inhibited with antioxidants, demonstrating the importance of Ox-GPC PAF-R agonists produced non-enzymatically. Host immune cells are required as CPAF-induced augmentation of tumor growth which is not seen in immunodeficient NOD SCID mice. Finally, depleting antibodies against IL-10 in WT mice or depletion of CD25-positive cells in FoxP3 EGFP transgenic mice block UVB and/or CPAF-induced tumor growth supporting a requirement for IL-10 and Tregs in this process. These findings indicate that UVB-generated Ox-GPCs with PAF-R agonistic activity enhance experimental murine melanoma tumor growth through targeting host immune cells, most notably Tregs, to mediate systemic immunosuppression.

30 November 2014 in Cancer Research
Verified
Journal Article
Open access
PDF file
Ravi SahuRavi Sahu
Ravi Sahu
JOJesus A. Ocana
Jesus A. Ocana
KHKathleen A. Harrison
Kathleen A. Harrison
MFMatheus Ferracini
Matheus Ferracini
CTChristopher E. Touloukian
Christopher E. Touloukian
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers
Oxidative stress suppresses host immunity by generating oxidized lipid agonists of the platelet-activating factor receptor (PAF-R). Because many classical chemotherapeutic drugs induce reactive oxygen species (ROS), we investigated whether these drugs might subvert host immunity by activating PAF-R. Here, we show that PAF-R agonists are produced in melanoma cells by chemotherapy that is administered in vitro, in vivo, or in human subjects. Structural characterization of the PAF-R agonists induced revealed multiple oxidized glycerophosphocholines that are generated nonenzymatically. In a murine model of melanoma, chemotherapeutic administration could augment tumor growth by a PAF-R–dependent process that could be blocked by treatment with antioxidants or COX-2 inhibitors or by depletion of regulatory T cells. Our findings reveal how PAF-R agonists induced by chemotherapy treatment can promote treatment failure. Furthermore, they offer new insights into how to improve the efficacy of chemotherapy by blocking its heretofore unknown impact on PAF-R activation. Cancer Res; 74(23); 7069–78. ©2014 AACR.

1 March 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RSRavi P. Sahu
Ravi P. Sahu
IPIrina Petrache
Irina Petrache
MDMary J. Van Demark
Mary J. Van Demark
BRBadri M. Rashid
Badri M. Rashid
JOJesus A Ocana
Jesus A Ocana
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers
Previous studies have established that pro-oxidative stressors suppress host immunity because of their ability to generate oxidized lipids with platelet-activating factor receptor (PAF-R) agonist activity. Although exposure to the pro-oxidative stressor cigarette smoke (CS) is known to exert immunomodulatory effects, little is known regarding the role of PAF in these events. The current studies sought to determine the role of PAF-R signaling in CS-mediated immunomodulatory effects. We demonstrate that CS exposure induces the generation of a transient PAF-R agonistic activity in the blood of mice. CS exposure inhibits contact hypersensitivity in a PAF-R–dependent manner as PAF-R–deficient mice were resistant to these effects. Blocking PAF-R agonist production either by systemic antioxidants or treatment with serum PAF-acetyl hydrolase enzyme blocked both the CS-mediated generation of PAF-R agonists and PAF-R–dependent inhibition of contact hypersensitivity (CHS) reactions, indicating a role for oxidized glycerophosphocholines with PAF-R agonistic activity in this process. In addition, cyclooxygenase-2 inhibition did not block PAF-R agonist production but prevented CS-induced inhibition of CHS. This suggests that cyclooxygenase-2 acts downstream of the PAF-R in mediating CS-induced systemic immunosuppression. Moreover, CS exposure induced a significant increase in the expression of the regulatory T cell reporter gene in Foxp3EGFP mice but not in Foxp3EGFP mice on a PAF-R–deficient background. Finally, regulatory T cell depletion via anti-CD25 Abs blocked CS-mediated inhibition of CHS, indicating the potential involvement of regulatory T cells in CS-mediated systemic immunosuppression. These studies provide the first evidence, to our knowledge, that the pro-oxidative stressor CS can modulate cutaneous immunity via the generation of PAF-R agonists produced through lipid oxidation.

15 June 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JOJesus A Ocana
Jesus A Ocana
EREric Romer
Eric Romer
RSRavi Sahu
Ravi Sahu
SPSven-Christian Pawelzik
Sven-Christian Pawelzik
GFGarret A FitzGerald
Garret A FitzGerald
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers
Platelet-activating factor (PAF) stimulates numerous cell types via activation of the G protein–coupled PAF receptor (PAFR). PAFR activation not only induces acute proinflammatory responses, but it also induces delayed systemic immunosuppressive effects by modulating host immunity. Although enzymatic synthesis and degradation of PAF are tightly regulated, oxidative stressors, such as UVB, chemotherapy, and cigarette smoke, can generate PAF and PAF-like molecules in an unregulated fashion via the oxidation of membrane phospholipids. Recent studies have demonstrated the relevance of the mast cell (MC) PAFR in PAFR-induced systemic immunosuppression. The current study was designed to determine the exact mechanisms and mediators involved in MC PAFR-mediated systemic immunosuppression. By using a contact hypersensitivity model, the MC PAFR was not only found to be necessary, but also sufficient to mediate the immunosuppressive effects of systemic PAF. Furthermore, activation of the MC PAFR induces MC-derived histamine and PGE2 release. Importantly, PAFR-mediated systemic immunosuppression was defective in mice that lacked MCs, or in MC-deficient mice transplanted with histidine decarboxylase– or cyclooxygenase-2–deficient MCs. Lastly, it was found that PGs could modulate MC migration to draining lymph nodes. These results support the hypothesis that MC PAFR activation promotes the immunosuppressive effects of PAF in part through histamine- and PGE2-dependent mechanisms.

1 November 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KHKathleen A. Harrison
Kathleen A. Harrison
EREric Romer
Eric Romer
JWJonathan Weyerbacher
Jonathan Weyerbacher
JOJesus A. Ocana
Jesus A. Ocana
RSRavi P. Sahu
Ravi P. Sahu
Jeffrey Bryant B TraversJeffrey Bryant B Travers
Jeffrey Bryant B Travers